Onemednet Corp (ONMD) Stock Price & Analysis
Onemednet Corp (ONMD) fell 7.15% to USD 0.6 as of June 11, 2026 at 09:49 UTC, according to Nexqual real-time market data.
ONMD last closed at USD 0.65; the session ranged USD 0.56–0.66 on volume of 940,746 shares. Market capitalization is $32.61M, with a 52-week range of USD 0.31–4.22 (NCM). Source: Nexqual, June 11, 2026 at 09:49 UTC.
Key Statistics (as of June 11, 2026 at 09:49 UTC)
| Price | USD 0.6 |
|---|---|
| Change | ▼ 7.15% (down) |
| Previous Close | USD 0.65 |
| Open | USD 0.63 |
| Day Range | USD 0.56 – 0.66 |
| 52-Week Range | USD 0.31 – 4.22 |
| Volume | 940,746 shares |
| Market Cap | $32.61M |
| Exchange | NCM |
Technical Analysis (ONMD)
Nexqual's technical model rates ONMD "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 11, 2026 at 09:49 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 31.82 (neutral) |
| vs SMA50 | Below (USD 0.89) |
| MACD | -0.07 (negative) |
Analyst Ratings (ONMD)
Wall Street analysts rate ONMD "None", per Nexqual as of June 11, 2026 at 09:49 UTC.
| Consensus Rating | None |
|---|
Earnings (ONMD)
Source: Nexqual, June 11, 2026 at 09:49 UTC.
Financials & Fundamentals (ONMD)
| Total Revenue | $1.32M |
|---|---|
| Revenue Growth (YoY) | -29.90% |
| Gross Margin | -50.00% |
| Operating Margin | -2658.33% |
| Profit Margin | -254.32% |
| Current Ratio | 0.27 |
| Total Cash | $233,000 |
| Total Debt | $837,000 |
| Free Cash Flow | $-9.65M |
Source: Nexqual, June 11, 2026 at 09:49 UTC.
Financial Health Score (ONMD)
Nexqual rates Onemednet Corp's overall financial health "Weak" across five dimensions, as of June 11, 2026 at 09:49 UTC.
| Growth | Critical — Revenue -30% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $233K cash, no debt |
| Cash Flow | Weak — FCF negative: -$10M, burning cash |
| Efficiency | Mixed — No data |
Ownership (ONMD)
| Insider Ownership | +70.93% |
|---|---|
| Institutional Ownership | +19.78% |
| Shares Outstanding | 54.43M |
| Float | 17.28M |
| Short % of Float | +1.68% |
Source: Nexqual, June 11, 2026 at 09:49 UTC.
Leadership (ONMD)
Onemednet Corp is led by Aaron Green (age 51), CEO, President & Director, per Nexqual as of June 11, 2026 at 09:49 UTC.
| CEO, President & Director | Aaron Green (age 51) |
|---|---|
| Founder, VP, Chief Medical Officer & Chairman | Jeffrey Yu (age 56) |
| CFO, Corporate Secretary & Director | Robert L. Golden (age 63) |
| Director of Operations | Khoi Ho |
| Chief Technology Officer | James Wang |
Major Backers & Investors (ONMD)
Notable institutional backers of Onemednet Corp include Exencial Wealth Advisors, LLC, Fidelity, Citigroup Inc., according to Nexqual as of June 11, 2026 at 09:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Exencial Wealth Advisors, LLC | 15.39% |
| Fidelity | 0.53% |
| Citigroup Inc. | 0.25% |
| Jane Street Group, LLC | 0.21% |
| Discovery Capital Management, LLC | 0.21% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.35% |
| Geode Capital | 0.62% |
| State Street | 0.21% |
| BlackRock | 0.13% |
Source: Nexqual, June 11, 2026 at 09:49 UTC.
From Onemednet Corp's Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- For example, the FDA has used Real World Data and Real World Evidence, derived from its Sentinel System, the largest multi-site distributed database in the world dedicated to medical product safety, for monitoring the safety of regulated products, in place of post-marketing studies.
- Violations of data protection regulations are subject to administrative penalties, civil money penalties and criminal prosecution, including corporate fines and personal liability.       Data Privacy   Certain of our operations are subject to regulation under the administrative simplification provisions of HIPAA.
- AI-integrated analytics and automation provide access to crucial insights from historical clinical trial Real World Data and Real World Evidence, expanding end-to-end clinical trial capabilities:     AI is driving ground-breaking leaps in protein structure identification, and advances in regulations are providing healthcare research organizations with access to Real World Data to accelerate clinical trial processes.
- Our capabilities allow us to render data non-identified while still maintaining data utility, thus protecting privacy while still advancing innovation.
Partnerships
- ONMD Canada's functional currency is the Canadian dollar.       Recent Developments     Private Placements   June 2025 Financing   On June 19, 2025, we entered into a securities purchase agreement with James Sixsmith ("Mr.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BDRX | Biodexa Pharmaceuticals plc | USD 3.01 | ▼ 7.67% |
| NIVF | NewGenIvf Group Limited | USD 0.54 | ▼ 1.65% |
| LUCY | Innovative Eyewear, Inc. | USD 0.88 | ▼ 3.84% |
| AKAN | Akanda Corp. | USD 13.81 | ▼ 5.73% |
| CTNT | Cheetah Net Supply Chain Servic | USD 1.92 | ▲ 6.67% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 11, 2026 at 09:49 UTC. This page is informational and not investment advice.